Patents by Inventor Chunhong He

Chunhong He has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclopropylamines as LSD1 inhibitors
    Patent number: 10174030
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: January 8, 2019
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Chunhong He, Xiaozhao Wang, Joel R. Courter, Fenglei Zhang, Wenqing Yao
  • IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS
    Publication number: 20180370977
    Abstract: The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.
    Type: Application
    Filed: May 2, 2018
    Publication date: December 27, 2018
    Inventors: Jincong Zhuo, Chunhong He, Wenqing Yao
  • Substituted tricyclic compounds as FGFR inhibitors
    Patent number: 10131667
    Abstract: The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: November 20, 2018
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Colin Zhang, Chunhong He, Liang Lu, Wenqing Yao
  • PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS
    Publication number: 20180327412
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Application
    Filed: May 4, 2018
    Publication date: November 15, 2018
    Inventors: Yun-Long Li, Xiaozhao Wang, Joseph Barbosa, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Taisheng Huang, Song Mei, Jincong Zhuo
  • Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
    Patent number: 10112950
    Abstract: The present invention is directed to imidazo[1,2-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: October 30, 2018
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Jingwei Li, Liang Lu, Yaping Sun, Xiaozhao Wang, Wenqing Yao, Colin Zhang, Jincong Zhuo
  • Heterocyclylamines as PI3K inhibitors
    Patent number: 10092570
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: October 9, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Wenyu Zhu, Joseph Glenn, Thomas P. Maduskuie, Jr., Richard B. Sparks, Brent Douty, Chunhong He
  • Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors
    Publication number: 20180282340
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Application
    Filed: March 20, 2018
    Publication date: October 4, 2018
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
  • Pyrrolopyrimidine derivatives as TAM inhibitors
    Patent number: 10053465
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: August 21, 2018
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Taisheng Huang, Song Mei, Jun Pan, Xiaozhao Wang, Yingda Ye
  • Imidazopyridines and imidazopyrazines as LSD1 inhibitors
    Patent number: 10047086
    Abstract: The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: August 14, 2018
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Leah C. Konkol, Neil Lajkiewicz, Liang Lu, Meizhong Xu, Wenqing Yao, Zhiyong Yu, Colin Zhang, Chunhong He
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 10040790
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: August 7, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Yaping Sun, Liang Lu, Wenqing Yao, Chunhong He, Fenglei Zhang
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20180179202
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: December 21, 2017
    Publication date: June 28, 2018
    Inventors: Liangxing Wu, Neil Lajkiewicz, Chunhong He, Kaijiong Xiao, Wenyu Zhu, Zhenwu Li, Song Mei, Chao Qi, Leah C. Konkol, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20180179197
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: December 21, 2017
    Publication date: June 28, 2018
    Inventors: Liangxing Wu, Jingwei Li, Chao Qi, Fenglei Zhang, Zhenwu Li, Wenyu Zhu, Zhiyong Yu, Kaijiong Xiao, Liang Lu, Song Mei, Ding-Quan Qian, Chunhong He, Yingda Ye, Meizhong Xu, Wenqing Yao
  • Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors
    Patent number: 9988387
    Abstract: The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: June 5, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Jincong Zhuo, Chunhong He, Wenqing Yao
  • Pyrrolotriazine compounds as tam inhibitors
    Patent number: 9981975
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: May 29, 2018
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Xiaozhao Wang, Chunhong He
  • Amido compounds and their use as pharmaceuticals
    Patent number: 9957229
    Abstract: The present invention relates to inhibitors of 11-? hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-? hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: May 1, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Wenqing Yao, Jincong Zhuo, Meizhong Xu, Colin Zhang, Brian W. Metcalf, Chunhong He, Ding-Quan Qian
  • Heterocyclic compounds as LSD1 inhibitors
    Patent number: 9944647
    Abstract: The present invention is directed to compounds of Formula I which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: April 17, 2018
    Assignee: Incyte Corporation
    Inventors: Chunhong He, Zhenwu Li, Liangxing Wu, Wenqing Yao, Fenglei Zhang
  • Imidazotriazines and imidazopyrimidines as kinase inhibitors
    Patent number: 9944645
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: April 17, 2018
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
  • IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS
    Publication number: 20170369487
    Abstract: The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: May 31, 2017
    Publication date: December 28, 2017
    Inventors: Liangxing Wu, Leah C. Konkol, Neil Lajkiewicz, Liang Lu, Meizhong Xu, Wenqing Yao, Zhiyong Yu, Colin Zhang, Chunhong He
  • IMIDAZOPYRAZINES AS LSD1 INHIBITORS
    Publication number: 20170369497
    Abstract: The present invention is directed to imidazo[1,2-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: June 5, 2017
    Publication date: December 28, 2017
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Jingwei Li, Liang Lu, Yaping Sun, Xiaozhao Wang, Wenqing Yao, Colin Zhang, Jincong Zhuo
  • HETEROCYCLYLAMINES AS PI3K INHIBITORS
    Publication number: 20170340641
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: August 10, 2017
    Publication date: November 30, 2017
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Wenyu Zhu, Joseph Glenn, Thomas P. Maduskuie, JR., Richard B. Sparks, Brent Douty, Chunhong He